Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy | Zendy

Clotilde Verlut | Zendy; Guillaume Mouillet | Zendy; Éloi Magnin | Zendy; J. Buffet-Miny | Zendy; G. Viennet | Zendy; F. Cattin | Zendy; Nora Clelia Billon-Grand | Zendy; Émilie Bonnet | Zendy; S. Servagi-Vernat | Zendy; J Godard | Zendy; R. Billon–Grand | Zendy; Antoine Petit | Zendy; Thierry Moulin | Zendy; L. Cals | Zendy; Xavier Pivot | Zendy; Elsa Curtit | Zendy

Open Access

Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy

Author(s) -

Clotilde Verlut,

Guillaume Mouillet,

Éloi Magnin,

J. Buffet-Miny,

G. Viennet,

F. Cattin,

Nora Clelia Billon-Grand,

Émilie Bonnet,

S. Servagi-Vernat,

J Godard,

R. Billon–Grand,

Antoine Petit,

Thierry Moulin,

L. Cals,

Xavier Pivot,

Elsa Curtit

Publication year - 2016

Publication title -

clinical medicine insights oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.601

H-Index - 26

ISSN - 1179-5549

DOI - 10.4137/cmo.s38474

Subject(s) - medicine , temozolomide , hazard ratio , chemoradiotherapy , radiation therapy , glioblastoma , concomitant , confidence interval , retrospective cohort study , multivariate analysis , chemotherapy , surgery , oncology , cancer research

Temozolomide and concomitant radiotherapy followed by temozolomide has been used as a standard therapy for the treatment of newly diagnosed glioblastoma multiform since 2005. A search for prognostic factors was conducted in patients with glioblastoma routinely treated by this strategy in our institution.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research